Finance

Lists
Outlook: 58.3% bullish·4.2% bearish
Go to analysis
INO:NASDAQ
Inovio Pharmaceuticals Inc
$1.51
0.00%
(0.00) 1D
$1.47
-2.58% (-0.039)
Pre-market
Closed: Nov 9, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INO...
Mkt. cap
155.49M
Avg. vol.
18.40M
Volume
1.28M
52-wk high
$2.72
52-wk low
$0.56
EPS
-$1.17
Beta
1.71
Shares outstanding
103.40M
No. of employees
112
Mkt. cap
155.49M
Avg. vol.
18.40M
Volume
1.28M
52-wk high
$2.72
52-wk low
$0.56
EPS
-$1.17
Beta
1.71
Shares outstanding
103.40M
No. of employees
112
News stories
From web sources and news partners
Profile
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development. Wikipedia
About Inovio Pharmaceuticals Inc
CEOJacqueline Shea
Employees112
Founded1999
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteinovio.com
Analyst ratings
Based on 3 analysts giving stock ratings to INO in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for INO in the last 3 months.
Highest
Current $1.51
$8.00 (+429.80%)
Average
$5.67 (+275.50%)
Lowest
$4.00 (+164.90%)
Analyst
Recommendation
Action
Price target
Projected
Date
Roger Song
Jefferies
Buy
Reiterated
$8.00
+429.8%
11/06/2026
Ram Selvaraju
H.C. Wainwright
Buy
Upgraded
$5.00
+231.1%
11/02/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$4.00
+164.9%
11/02/2026
Hartaj Singh
Oppenheimer
Buy
Maintained
$13.00
+760.9%
11/11/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
13.33M
10.26M
14.07M
10.83M
Cost of revenue
13.33M
10.26M
14.07M
10.83M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.88M
7.22M
7.88M
7.80M
Operating expense
7.88M
7.22M
7.88M
7.80M
Total operating expenses
21.21M
17.48M
21.95M
18.62M
Operating income
-21.21M
-17.48M
-21.95M
-18.62M
Other non operating income
-24.27M
21.17M
4.14M
12.73M
EBT including unusual items
-45.50M
3.76M
-19.68M
-6.01M
EBT excluding unusual items
-45.52M
3.75M
-19.48M
-5.53M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-45.50M
3.76M
-19.68M
-6.01M
Net profit margin
-
-
-
-
Earnings per share
-0.87
-0.28
-0.31
-0.24
Interest and investment income
552.11K
449.34K
439.59K
363.85K
Interest expense
-
-
-
-
Net interest expenses
552.11K
449.34K
439.59K
363.85K
Depreciation and amortization charges
-
-
-
-
EBITDA
-20.86M
-17.14M
-21.63M
-18.30M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps